Melphalan Hikma (Melphalan)

Melphalan works by attaching a chloroethyl group to the N7 position of guanine bases in DNA, creating covalent cross‑links between DNA strands. These cross‑links block DNA replication and transcription, leading to accumulation of DNA damage that the cell cannot repair, ultimately triggering apoptosis of rapidly dividing cancer cells.

The specific dose of Melphalan Hikma is individualized by the prescribing oncologist based on factors such as the type of cancer, disease stage, patient body surface area, renal and hepatic function, and prior treatment history. Dosing regimens are calculated to achieve therapeutic exposure while balancing the risk of toxicity, and are administered under close medical supervision.

Melphalan is classified as Pregnancy Category D, indicating evidence of fetal risk and that it should not be used during pregnancy unless the potential benefit justifies the risk. It is also excreted in breast milk, so breastfeeding is generally contraindicated while receiving treatment. Women of child‑bearing potential should use effective contraception throughout therapy and for a defined period after the last dose.

To order Melphalan Hikma from GNH India, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide and will request verification of trade or institutional credentials. After validation, the sales team provides pricing, availability, shipping details—including cold‑chain handling if required—and assists with the necessary import documentation to complete the purchase.

Compared with other alkylating agents such as cyclophosphamide, melphalan has a higher propensity for forming DNA cross‑links, which can result in greater cytotoxic potency but also a higher risk of myelosuppression. Unlike some newer targeted therapies, melphalan is non‑selective, affecting both cancerous and normal rapidly dividing cells, making its safety profile more comparable to traditional chemotherapy rather than to monoclonal antibodies or kinase inhibitors.

Melphalan Hikma should be stored at 2‑8 °C (refrigerated) in its original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold‑chain ensures drug stability and potency. If the product is inadvertently exposed to temperatures outside this range, it should be discarded.

Melphalan Hikma is administered by slow intravenous infusion, typically over 30–60 minutes, in a clinical setting such as an oncology centre or hospital. The infusion is prepared under aseptic conditions, and patients are monitored for infusion‑related reactions, vital signs, and blood counts before, during, and after administration.

The most serious risks associated with Melphalan include severe myelosuppression leading to life‑threatening infections, anemia or bleeding; secondary malignancies such as therapy‑related leukemia; pulmonary toxicity manifesting as interstitial pneumonitis; and rare cardiac dysfunction. Prompt recognition of infection signs, regular blood count monitoring, and appropriate supportive care are essential to mitigate these potentially fatal complications.

Melphalan should not be used in patients with known hypersensitivity to melphalan or any component of the formulation, in pregnant women unless absolutely necessary, in individuals with severe renal or hepatic impairment without dose adjustment, and in patients with uncontrolled active infections. Caution is also advised for those with pre‑existing cardiac or pulmonary disease.